PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
07-Jan-2022 F-star Therapeutics to Participate in Upcoming Investor Conferences F-star Therapeutics
07-Jan-2022 NICE Recommends MSD’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for Routine Commissioning for First-Line Treatment of Adults with Untreated Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)[1] MSD (Merck Sharp & Dohme)
07-Jan-2022 Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseases Sosei Heptares
07-Jan-2022 Imvaq Therapeutics Signs a Service and Commercial Product License to Use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform Imvaq Therapeutics
07-Jan-2022 Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference Tiziana Life Sciences
07-Jan-2022 Oxurion Provides Update on Clinical Pipeline Progress Oxurion
07-Jan-2022 Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines Sanofi
07-Jan-2022 Neurimmune enters into a collaboration and license agreement with AstraZeneca to develop and commercialize NI006 Neurimmune
07-Jan-2022 NICE recommends AbbVie’s RINVOQ® ▼ (upadacitinib) For Use in Adults with Active Psoriatic Arthritis AbbVie
07-Jan-2022 ​​​​​​​PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP PAION AG
07-Jan-2022 Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer Biotest AG
07-Jan-2022 SYNLAB acquires Sistemas Genómicos of the Ascires Group in Spain, further strengthening its European leadership in genetics SYNLAB AG
07-Jan-2022 MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance MorphoSys AG
07-Jan-2022 MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance MorphoSys AG
06-Jan-2022 Imvaq Therapeutics Signs a Service and Commercial Product License to Use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform B3C newswire
06-Jan-2022 Oral decitabine and cedazuridine (ASTX727) granted Orphan Drug Designation (ODD) by the European Commission for the treatment of Acute Myeloid Leukaemia (AML) Otsuka Pharmaceutical Europe Ltd.
06-Jan-2022 Voluntis and AliveCor Partner to Advance Management of Atrial Fibrillation for Patients with Cancer Voluntis and AliveCor
06-Jan-2022 ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies ONK Therapeutics
06-Jan-2022 Future Fertility Raises Series A to Progress First-In-Class AI-Enabled Fertility Solutions to Improve IVF Outcomes Future Fertility,
06-Jan-2022 Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment Valo Therapeutics